Preliminary In Vivo Evaluation of [I-131]-2-Iodo-D-Phenylalanine as a Potential Radionuclide Therapeutic Agent in R1M-Fluc Rhabdomyosarcoma Tumor-Bearing NuNu Mice Using Bioluminescent Imaging
Bauwens, Matthias × Wimana, Lena Keyaerts, Marleen Peleman, Cindy Lahoutte, Tony Kersemans, Ken Snykers, Sarah Vinken, Mathieu Mertens, John Bossuyt, Axel #
Mary ann liebert inc
Cancer biotherapy and radiopharmaceuticals vol:25 issue:2 pages:225-231
Background: Carrier-added [I-123]-2-iodo-D-phenylalanine (CA [I-123]-2-I-D-Phe) was previously found to have a preferential retention in tumors with a high tumor background contrast in animal models. A previous human dosimetry study demonstrated a favorable biodistribution and radiation burden in human subjects.